Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation. - Wikidata - awgldk - TriplyDB

Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation.

Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation.

http://www.wikidata.org/entity/Q43093991

about

GetReal in mathematical modelling: a review of studies predicting drug effectiveness in the real world.Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation.Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer's disease: systematic review and economic model.Florbetaben PET in the Early Diagnosis of Alzheimer's Disease: A Discrete Event Simulation to Explore Its Potential Value and Key Data Gaps.A Novel Application of Multiscale Entropy in Electroencephalography to Predict the Efficacy of Acetylcholinesterase Inhibitor in Alzheimer's Disease.Probabilistic Cost-Effectiveness Analysis of Vaccination for Mild or Moderate Alzheimer's Disease A systematic review of the cost-effectiveness of interventions for supporting informal caregivers of people with dementia residing in the community.Pharmacoeconomics of Alzheimer's disease (AD) treatment with cholinesterase inhibitors.Economic evaluation of treatment options in patients with Alzheimer's disease: a systematic review of cost-effectiveness analyses.The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review.When to use discrete event simulation (DES) for the economic evaluation of health technologies? A review and critique of the costs and benefits of DES.Systematic Review of Model-Based Economic Evaluations of Treatments for Alzheimer's Disease.Cost effectiveness of using cognitive screening tests for detecting dementia and mild cognitive impairment in primary care.Modeling cost-effectiveness of pharmaceuticals in Alzheimer's disease.How to include informal care in economic evaluations.Evolution of a cost-utility model of donepezil for Alzheimer's disease.Shunt surgery in idiopathic normal pressure hydrocephalus is cost-effective-a cost utility analysis.Early warning systems for the management of chronic heart failure: a systematic literature review of cost-effectiveness models.Clinical and cost implications of amyloid beta detection with amyloid beta positron emission tomography imaging in early Alzheimer's disease - the case of florbetapir.Alzheimer's disease Archimedes condition-event simulator: Development and validation.Developing WHO guidelines: Time to formally include evidence from mathematical modelling studies.Evaluating disease-modifying agents: a simulation framework for Alzheimer's disease.The Economic Impact of New Therapeutic Interventions on Neuropsychiatric Inventory (NPI) Symptom Scores in Patients with Alzheimer Disease.

P2860

Q30248472-DF1057FE-B7F8-45A3-9648-4E7970491469 Q34153726-33E35B9E-8CF4-49E3-AB07-94620290C105 Q34487826-F17F6D4A-7346-42D9-824E-27A5C7F403F3 Q34552387-7A375E2B-E7FD-4079-A901-5B5B78872CAE Q35668990-CFE9311E-064D-46E0-93CB-99BE64B2BEDF Q37044127-D51FC205-FD07-4337-865B-EF88989FA992 Q37911002-2CB0441A-0D67-4FEE-9D6E-DA218F769190 Q38000091-B4A2DE94-DF3E-4D2D-A5AC-5B7B9B7DF2DF Q38000337-7AE0EDD5-31C0-4FFF-9BE1-95D1E17072ED Q38167693-07BD6E5D-8502-4A7E-94E2-357683C84D39 Q38195815-EA263969-4225-47ED-B2C1-2B38A816AF5E Q38743343-E6E56448-FB3B-4131-9E31-DFB249746923 Q39164383-BC3D0F13-F635-4DFA-81DB-FE40A507A35B Q39583399-74819953-FC4E-45CA-919C-C7BFCF781B78 Q44709103-E709A6AA-69B5-4587-ADCB-8554EBC84147 Q45959235-3A40948C-33C7-4C20-A5C1-4E090EE518BA Q47575984-FAAA6953-2B51-4366-BA4C-54B8491DAED6 Q47784475-E91D614F-05F9-4DD8-A757-5C919F2A0CB4 Q50981551-AE5FC03D-E42F-4F39-B443-B84E280C4BE7 Q52568119-28473C09-DF59-43E9-83E8-33CBFC529DFB Q52646536-F65BCCB6-E197-4C89-B9C1-E67FFCC70585 Q53264801-27757138-2D26-4336-9A8A-70F8C0B07C18 Q54944297-268B5506-67EA-435B-B12D-53695BF29157

P2860

Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation.

http://www.wikidata.org/entity/Q43093991

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Cost effectiveness of donepezi ...... ing discrete-event simulation.

@en

Cost effectiveness of donepezi ...... ing discrete-event simulation.

@nl

type

label

Cost effectiveness of donepezi ...... ing discrete-event simulation.

@en

Cost effectiveness of donepezi ...... ing discrete-event simulation.

@nl

prefLabel

Cost effectiveness of donepezi ...... ing discrete-event simulation.

@en

Cost effectiveness of donepezi ...... ing discrete-event simulation.

@nl

P1433

Q43093991-7B2D0C8E-77D6-4A35-8AE4-1291D9A76AE6

P1476

Q43093991-209619D9-14D5-4CFB-B665-E2214E4617DF

P2093

Q43093991-129A003E-DD25-4B9E-BD79-9797AC56FA9E

Q43093991-2EAB2A4C-81F5-441E-96E4-71BB2E84B1D0

Q43093991-B6749B8D-8EEE-4D02-ABD5-58F879330FD1

Q43093991-FE4A0167-068B-4D85-9231-4DE609ECD90D

P2860

Q43093991-37F271D0-7DBE-46FF-9168-7D0C9B21BF72

Q43093991-5764BA86-059D-4681-8E09-90CA9E914F8B

Q43093991-78408716-2F68-4854-9E08-D8D2F74F5E1F

Q43093991-7F1513B7-0C2C-48AB-ADF0-4BECEB4B9649

Q43093991-C911377A-5F02-4252-A2BE-CABE39B73C50

Q43093991-FF5E3945-DD3B-4B8D-A86B-A1FAB11E92B8

P2888

Q43093991-61F0E69A-7273-425A-A2AC-DD95F279FCB4

P304

Q43093991-7C8BF348-7201-4DF9-9E23-A7EBDD18F333

P31

Q43093991-509E0E6B-A5C6-4111-9636-ADFD803438DE

P356

Q43093991-B33C1992-1052-4DD2-AC51-455F39662C36

P433

Q43093991-0645BCE3-091F-4575-A450-939780EBF271

P478

Q43093991-411A6B6D-F2F4-4A7F-8A76-4A77585DB8E0

P577

Q43093991-BE0B735D-02BA-4E6C-B760-68B4DAAC62E6

P5875

Q43093991-77A14891-D5F4-4566-B9C1-0CEC26C6B263

P6179

Q43093991-A46863BF-6537-4D51-AFA7-E2FDF373A6D7

P698

Q43093991-5F96FB43-42D9-4CDB-825A-ACB699EAA43A

P921

Q43093991-67B61C80-944B-4CE6-99F4-AE3489E2B29F

P356

11531870-000000000-00000

P1433

PharmacoEconomics

P1476

Cost effectiveness of donepezi ...... ing discrete-event simulation.

@en

P2093

Denis Getsios

http://www.w3.org/2001/XMLSchema#string

Grant D H Maclaine

http://www.w3.org/2001/XMLSchema#string

K Jack Ishak

http://www.w3.org/2001/XMLSchema#string

Steve Blume

http://www.w3.org/2001/XMLSchema#string

P2860

A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients.

A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.

A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.

A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration.

Assessment of health economics in Alzheimer's disease (AHEAD) based on need for full-time care.

P2888

11531870-000000000-00000

P304

411-427

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11531870-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43199997

http://www.w3.org/2001/XMLSchema#string

P6179

1018128412

http://www.w3.org/2001/XMLSchema#string

P698

20402542

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease